Apart from being used in the study of autoimmune diseases, this CD25 CD39 marker combination has been validated as a Treg marker in the study of TB, exhibiting a negative correlation with IL-17 T cells in peripheral blood (Chiacchio et al., 2009; de Cassan et al., 2010). This evidence concerns the gene ENTPD1 and autoimmune disease.